peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

ERR agonist

SLU-PP-332

Published evidence · coverage incomplete

Anatomy in the research

Anatomy evidence is still being assembled.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

This publication has no anatomy passages that meet our source-linking checks yet. Read the available findings ↓

General anatomy view only. No peptide-specific structures are highlighted.

At a glance

What is it—and why does it matter?

An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

How does it work?

Target, response, and disposition.

Mechanism

The Abstract reports that liquid chromatography-high-resolution mass spectrometry (LC-MS/HRMS) was used to analyze SLU-PP-332 metabolites.

Sources[1]pubmedAnalysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.Metabolites were analyzed using liquid chromatography-high-resolution mass spectrometry (LC-MS/HRMS).
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Metabolites were analyzed using liquid chromatography-high-resolution mass spectrometry (LC-MS/HRMS).”

    Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes. · Abstract

    pubmed:41688415:521ff63a3009:521ff63a3009

Mechanism

The Abstract states the in vitro system used to produce SLU-PP-332 Phase I and II metabolites was pooled human liver S9 fractions.

Sources[1]pubmedAnalysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.The aim of the study was identification of Phase I and II metabolites generated in vitro using pooled human liver S9 fractions.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The aim of the study was identification of Phase I and II metabolites generated in vitro using pooled human liver S9 fractions.”

    Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes. · Abstract

    pubmed:41688415:521ff63a3009:521ff63a3009

What has been studied?

What the evidence says.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, identity, interaction, regulatory, safety
  • 22 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (16), assurance_score_below_0.72 (5), current_regulatory_source_required (2), extraction_ambiguity (25), high_risk_requires_regulatory_or_two_independent_sources (5), no_direct_support (21)
  • A source-backed introductory overview is not yet available.

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes. ↗

    pubmed · published 2026-03-01 · retrieved 2026-08-29T08:37:13Z

Publication history and provenance

Version 1 · Automated assessment · 2026-08-29T08:37:13Z

60cef062b89aea867795d61d17674b015fdd904d3239301dc281a56e6fc7ced3